Eli Lilly and Co

Naloxone essential for reversing opioid overdoses; FDA approves Vertex's cystic fibrosis treatment and Eli Lilly's Zepbound for weight loss and sleep apnea.

FDA approves Zepbound for treating moderate-to-severe obstructive sleep apnea and obesity. Trials show Zepbound reduces breathing disruptions and aids weight loss, but side effects include digestive issues and potential thyroid tumors.

In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.

The FDA approved Eli Lilly's Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, based on SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index (AHI) and substantial weight loss. Zepbound, which reduces appetite and food intake, offers a new non-invasive treatment option for OSA, a condition affecting 30 million Americans but significantly underdiagnosed. Common side effects include gastrointestinal issues, and patients with a history of medullary thyroid carcinoma should avoid the drug.

Novo Nordisk's CagriSema trial disappoints, causing $125B market value drop. Competition in weight-loss drug market intensifies with generic versions emerging. FDA approval of Vertex Pharma's cystic fibrosis treatment highlights pharmaceutical innovation.

The FDA approved Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnea in obese individuals. It should be used with a reduced-calorie diet and increased physical activity. Clinical trials showed significant improvements in sleep apnea symptoms and weight loss.

The FDA approved Zepbound, the first prescription drug for obstructive sleep apnea, for people with obesity and moderate to severe sleep apnea. Studies showed improvement in symptoms with Zepbound compared to a placebo. The drug's compound, tirzepatide, also aids weight loss and is used in diabetes treatment. The approval may increase demand for obesity medications and influence insurance coverage.

US FDA approves Zepbound, a weight-loss drug by Eli Lilly, for treating moderate to severe obstructive sleep apnea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.

Zepbound, approved for treating obstructive sleep apnea (OSA) in obese patients, is the first medication to significantly improve moderate-to-severe OSA and aid long-term weight loss. OSA, underdiagnosed and linked to obesity and Type 2 diabetes, involves airway blockage during sleep causing apneic episodes. Clinical trials showed Zepbound eliminated OSA symptoms in 43% and 51% of patients.

FDA approves Eli Lilly's Zepbound for moderate-to-severe sleep apnea and obesity, marking the first medication for obstructive sleep apnea. Zepbound, a GLP-1 drug, should be used with a reduced-calorie diet and increased physical activity. Studies show it reduces breathing pauses and promotes weight loss, though side effects include nausea and stomach discomfort. Concerns over GLP-1 medication prices persist.